Latest SEC filings for Vertex Pharmaceuticals Incorporated (VRTX) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
Upadhyay Suketu (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
SACHS BRUCE I (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Garber Alan M (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Liu Joy, listed as EVP and Chief Legal Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 978 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Liu Joy filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Bozic Carmen, listed as EVP and CMO at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 2,329 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
VERTEX PHARMACEUTICALS INC / MA filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Bozic Carmen filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Bozic Carmen, listed as EVP and CMO at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 2,329 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
McKechnie Duncan, listed as EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 2,633 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bozic Carmen filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
McKechnie Duncan filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
McKechnie Duncan, listed as EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 2,437 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Liu Joy, listed as EVP and Chief Legal Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 892 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
McKechnie Duncan filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.